mongersen
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
4
Phase 4
0
Earliest trial started Apr 8, 2015 (NCT02367183)
Timeline
Indications
Mechanism of action
- SMAD-7 mRNAANTISENSE INHIBITOR
SMAD-7 mRNA antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ged-0301
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02974322 | Phase 3 | Apr 15, 2017 | Celgene |
| NCT02957474 | Phase 1 | Nov 1, 2016 | Celgene |
| NCT02641392 | Phase 3 | Jul 25, 2016 | Celgene |
| NCT02685683 | Phase 3 | Apr 29, 2016 | Celgene |
| NCT02601300 | Phase 2 | Dec 14, 2015 | Celgene |
| NCT02596893 | Phase 3 | Dec 8, 2015 | Celgene |
| NCT02367183 | Phase 1 | Apr 8, 2015 | Celgene |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 7 | 7 | 3 | 2015 |
1 organizations
Page 1 / 1